Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 35Esophageal Squamous Cell Carcinoma 19Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Squamous Cell Carcinoma of Head and Neck 15Triple Negative Breast Neoplasms 14Breast Neoplasms 12Uterine Cervical Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 10Melanoma 10Carcinoma, Renal Cell 9Stomach Neoplasms 8Recurrence 8Head and Neck Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Advanced Solid Tumor 5Urinary Bladder Neoplasms 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Liver Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4Solid Tumor 3Nasopharyngeal Neoplasms 3

Interventions

toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1camrelizumab 1atezolizumab 1Taxes 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced or Metastatic Solid Tumors × toripalimab × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡